PDF(Pubmed)
Abstract：
UNASSIGNED: Abnormal lipid levels have been associated with cancer incidence and progression. However, limited studies have investigated the relationship between apolipoprotein A-I (ApoA-I) and colorectal cancer (CRC). This study assessed the significance of ApoA-I levels in progression-free survival (PFS) and overall survival (OS) of patients with CRC.
UNASSIGNED: Survival curves were compared using Kaplan-Meier analysis, while the predictive values of various lipid indicators in CRC prognosis were evaluated based on receiver operating characteristic curves. The factors influencing PFS and OS in patients with CRC were analyzed using Cox proportional hazards regression models. Finally, the relationship between ApoA-I level and disease recurrence was investigated through logistic regression analysis. The optimal Apo-I level was determined through maximally selected rank statistics.
UNASSIGNED: Using the optimal ApoA-I cutoff value (0.9 g/L), the 1,270 patients with CRC were categorized into low (< 0.9 g/L, 275 cases) and high (≥0.9 g/L, 995 cases) ApoA-I groups. Compared with other lipid indicators, ApoA-I demonstrated superior predictive accuracy. The high ApoA-I group exhibited significantly higher survival rates than the low ApoA-I group (PFS, 64.8% vs. 45.2%, P < 0.001; OS, 66.1% vs. 48.6%, P < 0.001). Each one-standard-deviation increase in ApoA-I level was related to a 12.0% decrease in PFS risk (hazard ratio [HR] 0.880; 95% confidence interval [CI], 0.801-0.968; P = 0.009) and an 11.2% decrease in OS risk (HR 0.888; 95%CI, 0.806-0.978; P = 0.015). Logistic regression analysis revealed that patients with low ApoA-I had a 32.5% increased risk of disease recurrence (odds ratio [OR] 0.675; 95%CI, 0.481-0.946; P = 0.0225) compared with those with high ApoA-I. PFS/OS nomograms based on ApoA-I demonstrated excellent prognostic prediction accuracy.
UNASSIGNED: Serum ApoA-I level may be a valuable and non-invasive tool for predicting PFS and OS in patients with CRC.
UNASSIGNED: Survival curves were compared using Kaplan-Meier analysis, while the predictive values of various lipid indicators in CRC prognosis were evaluated based on receiver operating characteristic curves. The factors influencing PFS and OS in patients with CRC were analyzed using Cox proportional hazards regression models. Finally, the relationship between ApoA-I level and disease recurrence was investigated through logistic regression analysis. The optimal Apo-I level was determined through maximally selected rank statistics.
UNASSIGNED: Using the optimal ApoA-I cutoff value (0.9 g/L), the 1,270 patients with CRC were categorized into low (< 0.9 g/L, 275 cases) and high (≥0.9 g/L, 995 cases) ApoA-I groups. Compared with other lipid indicators, ApoA-I demonstrated superior predictive accuracy. The high ApoA-I group exhibited significantly higher survival rates than the low ApoA-I group (PFS, 64.8% vs. 45.2%, P < 0.001; OS, 66.1% vs. 48.6%, P < 0.001). Each one-standard-deviation increase in ApoA-I level was related to a 12.0% decrease in PFS risk (hazard ratio [HR] 0.880; 95% confidence interval [CI], 0.801-0.968; P = 0.009) and an 11.2% decrease in OS risk (HR 0.888; 95%CI, 0.806-0.978; P = 0.015). Logistic regression analysis revealed that patients with low ApoA-I had a 32.5% increased risk of disease recurrence (odds ratio [OR] 0.675; 95%CI, 0.481-0.946; P = 0.0225) compared with those with high ApoA-I. PFS/OS nomograms based on ApoA-I demonstrated excellent prognostic prediction accuracy.
UNASSIGNED: Serum ApoA-I level may be a valuable and non-invasive tool for predicting PFS and OS in patients with CRC.
摘要：
■异常的脂质水平与癌症的发生和进展有关。然而,有限的研究调查了载脂蛋白A-I（ApoA-I）与结直肠癌（CRC）之间的关系。这项研究评估了ApoA-I水平在CRC患者的无进展生存期（PFS）和总生存期（OS）中的意义。
■使用Kaplan-Meier分析比较了生存曲线，同时根据受试者工作特征曲线评估各种血脂指标在CRC预后中的预测值。采用Cox比例风险回归模型分析影响CRC患者PFS和OS的因素。最后,通过logistic回归分析研究ApoA-I水平与疾病复发的关系。最佳Apo-I水平是通过最大程度地选择等级统计来确定的。
■使用最佳ApoA-I截止值（0.9g/L），1,270例CRC患者被归类为低(<0.9g/L，275例）和高（≥0.9g/L，995例)ApoA-I组。与其他血脂指标相比，ApoA-I表现出优异的预测准确性。高ApoA-I组的生存率明显高于低ApoA-I组（PFS，64.8%与45.2%,P<0.001;OS,66.1%vs.48.6%,P<0.001)。ApoA-I水平的每一个标准差的增加与PFS风险的12.0%的降低相关(风险比[HR]0.880;95%置信区间[CI],0.801-0.968；P=0.009）和OS风险降低11.2%（HR0.888；95CI，0.806-0.978；P=0.015）。Logistic回归分析显示，与ApoA-I高的患者相比，ApoA-I低的患者疾病复发风险增加32.5％（比值比[OR]0.675；95CI，0.481-0.946；P=0.0225）。基于ApoA-I的PFS/OS列线图显示了出色的预后预测准确性。
■血清ApoA-I水平可能是预测CRC患者PFS和OS的有价值的非侵入性工具。
■使用Kaplan-Meier分析比较了生存曲线，同时根据受试者工作特征曲线评估各种血脂指标在CRC预后中的预测值。采用Cox比例风险回归模型分析影响CRC患者PFS和OS的因素。最后,通过logistic回归分析研究ApoA-I水平与疾病复发的关系。最佳Apo-I水平是通过最大程度地选择等级统计来确定的。
■使用最佳ApoA-I截止值（0.9g/L），1,270例CRC患者被归类为低(<0.9g/L，275例）和高（≥0.9g/L，995例)ApoA-I组。与其他血脂指标相比，ApoA-I表现出优异的预测准确性。高ApoA-I组的生存率明显高于低ApoA-I组（PFS，64.8%与45.2%,P<0.001;OS,66.1%vs.48.6%,P<0.001)。ApoA-I水平的每一个标准差的增加与PFS风险的12.0%的降低相关(风险比[HR]0.880;95%置信区间[CI],0.801-0.968；P=0.009）和OS风险降低11.2%（HR0.888；95CI，0.806-0.978；P=0.015）。Logistic回归分析显示，与ApoA-I高的患者相比，ApoA-I低的患者疾病复发风险增加32.5％（比值比[OR]0.675；95CI，0.481-0.946；P=0.0225）。基于ApoA-I的PFS/OS列线图显示了出色的预后预测准确性。
■血清ApoA-I水平可能是预测CRC患者PFS和OS的有价值的非侵入性工具。
